Reve Pharma underwent a USFDA audit conducted by Mr. Jake Lane from the US Food and Drug Administration on May 27th and 28th, 2024. These audits are crucial as they assess manufacturing facilities for compliance with relevant laws and regulations. Mr. Lane Jake provided guidance to the Reve team on various compliance and regulatory matters during his two-day visit to the company. The Reve team successfully passed the audit, marking a significant milestone in the company’s growth and potential for attracting customers.
Mr. Milind Katariya and Mrs. Anjali Katariya (Founders and Directors of the company) has set the great example for people who wants to achieve their dream. Reve team has shown a great teamwork, dedication and leadership in the period.
